

CorMedix Inc.  
Form 4  
February 04, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC., 1430 US  
HIGHWAY 206, SUITE 200

(Street)

BEDMINSTER, NJ US 07921

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

CorMedix Inc. [CRMD]

3. Date of Earliest Transaction  
(Month/Day/Year)

02/04/2016

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$0.001 par value per share	02/04/2016		M	30,000	A \$ 0.29	147,399	D
Common Stock, \$0.001 par value per share					174,741	I <sup>(1)</sup>	Wade Capital Corporation Money Purchase Plan
					10,000	I <sup>(1)</sup>	

Common  
Stock,  
\$0.001 par  
value per  
share

Reporting  
Person's  
Wife

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (right to buy)	\$ 2.02					(2)	01/09/2024	Common Stock, \$0.001 par value per share	200,000
Stock Option (right to buy)	\$ 2.02					(7)	01/09/2024	Common Stock, \$0.001 par value per share	30,000
Swries C-3 Non-Voting Convertible Preferred Stock	\$ 1					(3)	(3)	Common Stock, \$0.001 par value per share	45,000
Warrant (right to purchase Common Stock)	\$ 0.9 (4)					01/08/2015	01/08/2020	Common Stock, \$0.001 par value per share	22,500
Series C-3 Non-Voting Convertible	\$ 1					(4)	(4)	Common Stock, \$0.001	30,000

Preferred Stock								par value per share	
Warrant (right to purchase Common Stock)	\$ 0.9 <sup>(4)</sup>					01/08/2015	01/08/2020	Common Stock, \$0.001 par value per share	15,0
Stock Option (right to buy)	\$ 0.9					<sup>(5)</sup>	03/20/2023	Common Stock, \$0.001 par value per share	120,0
Stock Option (right to buy)	\$ 0.68					<sup>(6)</sup>	12/05/2022	Common Stock, \$0.001 par value per share	150,0
Stock Option (right to buy)	\$ 0.29	02/04/2016		M	30,000	<sup>(7)</sup>	01/06/2022	Common Stock, \$0.001 par value per share	30,0
Stock Option (right to buy)	\$ 1.1					<sup>(8)</sup>	08/11/2021	Common Stock, \$0.001 par value per share	30,0
Stock Option (right to buy)	\$ 5.62					<sup>(7)</sup>	03/01/2025	Common Stock, \$0.001 par value per share	50,0

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lefkowitz Steven W C/O CORMEDIX INC. 1430 US HIGHWAY 206, SUITE 200 BEDMINSTER, NJ US 07921	X			

## Signatures

/s/Alexander M. Donaldson by Power of  
Attorney

02/04/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
- (2) The options vested 100% on January 10, 2014.  
On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (3) On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The warrant exercise price was decreased from \$1.25 per share to \$0.90 per share effective September 15, 2014. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (4) These options vest quarterly over two years beginning June 13, 2013.
- (5) These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- (6) The options vest in full on the first anniversary of the date of grant.
- (8) The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.